Growth Ratio Summary

Growth Score : 10.00

Alembic Pharmaceuticals demonstrates strong growth across various metrics. The company has experienced high revenue growth, indicating increasing demand for its products. Operating profit growth and earnings per share growth are also robust, reflecting improved profitability. Asset growth and net income growth indicate the company is expanding its asset base and increasing its net earnings. This indicates a positive trajectory for the company's future performance.

Financial Ratio Summary

Financial Score : 7.80

The company's financial performance is positive. The adjusted earnings per share and cash earnings per share are robust, reflecting strong profitability. The book value per share is also high, indicating the company has substantial equity. The dividend per share is adequate, providing a return to shareholders. However, capital expenditures are relatively low, which is an area that needs to be focused, potentially limiting future growth opportunities. Overall, the company's financial health is good.

Profitability Ratio Summary

Profitability Score : 10.00

Alembic Pharmaceuticals demonstrates excellent profitability across various metrics. The gross profit margin, return on capital employed, return on equity, return on assets, operating margin, and net margin are all high, indicating efficient operations and strong financial performance. This indicates the company is generating substantial profits from its operations and investments. The company is able to generate profits from assets.

Efficiency Ratio Summary

Efficiency Score : 3.33

Alembic Pharmaceuticals' efficiency in utilizing its assets is an area of concern. The fixed asset turnover ratio and capital turnover ratio are low, suggesting the company is not generating enough revenue from its fixed assets or overall capital. Inventory turnover is also low, with a high number of days sales in inventory, indicating slow-moving inventory. The receivables turnover ratio is moderate, with receivable days suggesting room for improvement in collecting payments. This indicates a need to improve asset utilization and working capital management.

Coverage Ratio Summary

Coverage Score : 8.40

The company's ability to cover its interest and dividend payments is strong. The interest coverage ratio is high, indicating the company can easily meet its interest obligations. The equity dividend coverage ratio is moderate, suggesting the company can comfortably cover its dividend payments to shareholders. This indicates a solid financial position and the company is able to manage its financial obligations effectively.

Solvency Ratio Summary

Solvency Score : 10.00

Alembic Pharmaceuticals exhibits a very strong financial position with minimal debt. The debt ratio and debt-to-equity ratio are exceptionally low, indicating a conservative approach to borrowing. The equity ratio is very high, reflecting a substantial equity base. This indicates that the company is primarily financed by equity rather than debt, which reduces financial risk. This financial structure provides a solid foundation for future growth and stability.

Liquidity Ratio Summary

Liquidity Score : 4.76

The company's ability to meet its short-term obligations is somewhat moderate. While the current and quick ratios suggest an acceptable level of liquid assets, the cash ratio indicates a limited amount of cash on hand to cover immediate liabilities. The operating cash flow ratio is also relatively low, suggesting potential challenges in generating sufficient cash from operations. While adequate, the company needs to focus on improving cash management to enhance its short-term financial health.